Can I Take St. John's Wort with PT-141 (Bremelanotide)?

How PT-141 (Bremelanotide) Works in the Body

Bremelanotide is a synthetic cyclic peptide that activates melanocortin-4 receptors (MC4R) in the central nervous system. That activation triggers downstream dopaminergic and oxytocinergic signaling in hypothalamic circuits tied to sexual desire. The FDA approved it in June 2019 under the brand name Vyleesi for HSDD in premenopausal women, based on two phase 3 trials (RECONNECT 1 and RECONNECT 2) enrolling a combined 1,247 participants [1].

Route and Dosing

PT-141 is self-administered as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity. The label limits use to one dose per 24 hours and no more than eight doses per month [1].

Metabolism and Elimination

Bremelanotide is a peptide. Peptides are broken down primarily by hydrolysis and peptidase activity, not by the cytochrome P450 (CYP) system the way most small-molecule drugs are. The Vyleesi prescribing information notes that bremelanotide is "not expected to be a substrate of CYP enzymes at clinically relevant concentrations" [1]. This detail matters because it limits the size of any purely pharmacokinetic interaction with St. John's Wort. The terminal half-life is approximately 2.7 hours, and roughly 65% of the drug is recovered in urine as metabolized fragments [2].

How St. John's Wort Affects Drug Metabolism

St. John's Wort contains hyperforin, the compound primarily responsible for its antidepressant properties and its well-documented enzyme-inducing effects. Hyperforin activates the pregnane X receptor (PXR), which upregulates transcription of CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein (P-gp) [3].

The Scope of CYP3A4 Induction

A 2012 systematic review in Clinical Pharmacology & Therapeutics found that St. John's Wort reduced the area under the curve (AUC) of CYP3A4 substrates by 20% to 65% depending on the co-administered drug [3]. Clinically significant interactions have been confirmed with cyclosporine, oral contraceptives, warfarin, HIV protease inhibitors, and dozens of other medications [4].

Onset and Offset of Induction

Enzyme induction does not happen overnight. Full induction typically requires 10 to 14 days of consistent St. John's Wort dosing (usually 300 mg standardized extract three times daily). After discontinuation, enzyme activity takes another 10 to 14 days to return to baseline because the body must degrade the excess enzyme protein it produced [3].

The PT-141 and St. John's Wort Interaction: Two Layers

The interaction between bremelanotide and St. John's Wort operates on two distinct planes. Neither has been studied in a formal drug-interaction trial, so available evidence comes from mechanism-based reasoning, the Vyleesi FDA label, and the known pharmacology of hyperforin.

Layer 1: Pharmacokinetic (Likely Minor)

Because bremelanotide is a peptide metabolized mainly by hydrolysis, CYP3A4 induction should have a limited direct effect on its clearance. There is a caveat. Some peptides interact with P-glycoprotein efflux transporters in the gut wall and blood-brain barrier. St. John's Wort induces P-gp expression [3]. If bremelanotide is a P-gp substrate (this has not been fully characterized in published literature), then P-gp induction could reduce its CNS penetration and blunt its efficacy. The net pharmacokinetic risk is plausible but unconfirmed.

Layer 2: Pharmacodynamic (More Concerning)

This is where the real clinical worry sits. Bremelanotide activates MC4R, which increases dopamine release in mesolimbic pathways [2]. St. John's Wort inhibits reuptake of serotonin, norepinephrine, and dopamine [5]. Overlapping dopaminergic stimulation could amplify side effects such as nausea (reported in 40% of bremelanotide users in RECONNECT trials), flushing, and transient blood pressure elevation [1].

The Vyleesi label already warns that bremelanotide causes a transient increase in systolic blood pressure of about 6 mmHg and a decrease in heart rate of about 5 bpm within the first hour after injection [1]. Adding St. John's Wort's mild noradrenergic effects on top of that creates unpredictable hemodynamic territory, particularly in patients with pre-existing hypertension.

The FDA's Natural Medicines Comprehensive Database classifies combinations that raise serotonergic tone alongside dopaminergic agents as warranting clinical monitoring [6].

What the FDA Label Says About CNS and Blood Pressure Interactions

The Vyleesi prescribing information includes two relevant warnings that apply here even though St. John's Wort is not called out by name.

Blood Pressure Warning

Section 5.2 of the label states: "Bremelanotide transiently increases blood pressure. Use in patients with uncontrolled hypertension or known cardiovascular disease has not been studied and is not recommended" [1]. Any concurrent agent that independently raises blood pressure or catecholamine tone (including St. John's Wort's norepinephrine reuptake inhibition) adds to that concern.

Naltrexone and Opioid Interaction Precedent

The label explicitly contraindicates bremelanotide use within a short window of naltrexone because of pharmacodynamic overlap in CNS receptor modulation [1]. While St. John's Wort is not an opioid antagonist, the principle is the same: avoid stacking agents that hit overlapping CNS pathways when the resulting interaction has not been formally studied.

Clinical Guidance: Should You Combine Them?

The safest approach is straightforward. Avoid concurrent use if possible.

If You Have Not Started Either Agent

Choose one. If your primary concern is HSDD, discuss bremelanotide with your prescriber and use an evidence-based antidepressant (if needed) whose interaction profile has been studied more thoroughly. SSRIs such as sertraline have been co-administered with bremelanotide in clinical development without dose-limiting interactions [1].

If You Are Already Taking St. John's Wort and Want to Start PT-141

Stop St. John's Wort and wait at least 14 days before your first bremelanotide injection. This allows CYP3A4 and P-gp expression to normalize. Taper rather than stop abruptly if you have been taking it daily for more than 8 weeks to avoid rebound mood changes [5].

If You Are Already Taking Both

Tell your prescriber immediately. Monitor blood pressure before and 1 hour after each PT-141 injection. Track nausea severity, flushing duration, and any new mood symptoms (agitation, restlessness, insomnia) that could signal excessive serotonergic or dopaminergic stimulation. If nausea exceeds baseline or systolic blood pressure rises more than 10 mmHg from your pre-injection reading, withhold the next dose and call your clinician.

Blood Pressure Monitoring Protocol

Because both agents influence vascular tone through different mechanisms, a structured monitoring plan is non-negotiable for anyone using both substances.

Pre-Injection Baseline

Take a seated blood pressure reading before each PT-141 injection. Record it. Readings above 140/90 mmHg should prompt you to skip that dose and contact your prescriber.

Post-Injection Check

Repeat the blood pressure measurement 60 minutes after injection. An increase of more than 6 mmHg systolic is consistent with the expected bremelanotide effect [1]. Anything above 10 mmHg systolic increase, or any diastolic rise exceeding 5 mmHg, warrants clinical review before the next dose.

Weekly Average

If you are using PT-141 multiple times per month, maintain a weekly blood pressure log. Share it at each prescriber visit. The American Heart Association recommends home monitoring with a validated oscillometric cuff for patients on vasoactive medications [7].

Who Is Most at Risk?

Not all patients face the same level of concern. Three groups should exercise extra caution.

Patients on Other Serotonergic Agents

Anyone already taking an SSRI, SNRI, tramadol, or triptan alongside St. John's Wort is already at elevated serotonin syndrome risk. Adding bremelanotide's dopaminergic activity to that mix further destabilizes monoamine balance. The RECONNECT trials excluded patients on flibanserin for this reason [1].

Patients with Cardiovascular Risk Factors

Hypertension, coronary artery disease, and a history of stroke are all listed in the Vyleesi label as populations where safety data are limited [1]. St. John's Wort's mild hemodynamic effects become clinically relevant in these patients, even though they are usually inconsequential in healthy adults.

Patients Using PT-141 Off-Label at Higher Doses

Off-label use in men for erectile dysfunction sometimes involves doses of 2 mg or higher administered multiple times per week. Higher exposure increases the magnitude of blood pressure changes and nausea, amplifying any additive interaction with St. John's Wort [8].

Alternative Supplements for Mood Support During PT-141 Use

If you rely on St. John's Wort for mild depressive symptoms and want to continue bremelanotide, consider alternatives with fewer CYP and monoamine interactions.

Magnesium glycinate (400 mg daily) has shown modest anxiolytic and mood-stabilizing effects in a 2017 randomized trial (N=126) published in PLOS ONE without CYP3A4 induction or significant serotonergic activity [9]. Omega-3 fatty acids (EPA-predominant, 1 to 2 g daily) demonstrated a small antidepressant effect in a 2019 meta-analysis of 26 RCTs (N=2,160) in Translational Psychiatry, again with no known CYP enzyme induction [10].

Neither option replaces formal psychiatric treatment for moderate-to-severe depression. Discuss any supplement change with your prescriber.

How Long Does the Interaction Window Last?

Timing matters. Here is what the pharmacokinetic data tell us.

Bremelanotide's half-life is approximately 2.7 hours, meaning it is effectively cleared within 12 to 14 hours of injection [2]. St. John's Wort enzyme induction, by contrast, persists for 10 to 14 days after the last dose [3]. The asymmetry is important: a single missed dose of St. John's Wort does not eliminate the interaction. Full enzyme de-induction requires roughly two weeks of zero hyperforin exposure.

If you stop St. John's Wort on a Monday, the earliest you should consider a bremelanotide injection (assuming your prescriber agrees) is the Monday two weeks later. Do not estimate based on when symptoms of the herbal wear off. Subjective mood changes from stopping St. John's Wort may appear within 3 to 5 days, but the enzyme induction outlasts the mood effect.

What Does the Research Gap Look Like?

No published clinical trial has directly studied the bremelanotide and St. John's Wort combination. The RECONNECT phase 3 program excluded patients on "any medication or supplement that could confound efficacy or safety assessments," which included St. John's Wort [1]. As a result, every recommendation in this article is based on mechanism-of-action reasoning, class-effect extrapolation, and the known pharmacology of hyperforin.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not address herbal supplement interactions with bremelanotide specifically but recommends "reviewing the patient's complete medication and supplement list before initiating any pharmacotherapy for HSDD" [11].

A 2020 narrative review in The Journal of Clinical Pharmacology cataloged over 150 clinically significant St. John's Wort drug interactions and concluded that "any co-prescribed medication should be evaluated for CYP3A4, CYP2C9, or P-gp substrate status before concomitant use" [4].

Patients currently using both agents represent an uncharted population. Report any adverse effects to the FDA MedWatch program (1-800-FDA-1088) so that post-market surveillance can fill the evidence gap.